InnoCan Pharma

Innocan Pharma is a pharmaceutical technology company focused on developing innovative drug delivery platform technologies that incorporate cannabinoids science to treat various conditions and improve patient quality of life. Their primary areas of focus are in the pharmaceuticals and consumer wellness segments. In the pharmaceuticals segment, Innocan is developing two drug delivery platforms: the LPT CBD-loaded liposome platform for targeted delivery and controlled release of CBD, and the CLX CBD-loaded exosomes platform, which aims to target the central nervous system. In consumer wellness, Innocan develops and markets a range of self-care products.

Innocan Pharma is driven by a multidisciplinary team of experienced professionals, including Iris Bincovich, Ron Mayron, Professor Chezy Barenholz, and Professor Daniel Offen. The company's research is largely based in Israel, which has become a global leader in medical cannabis research and innovation. Innocan Pharma's commitment to innovation, combined with its strong team and strategic focus on cannabinoid-based therapies, positions it as a promising player in the rapidly growing pharmaceutical and wellness sectors.

Innocan Pharma is a pharmaceutical technology company focused on developing innovative drug delivery platform technologies utilizing cannabinoids science to treat various conditions and improve patients’ quality of life. Innocan operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on two drug delivery technologies: LPT CBD-loaded liposome platform and CLX CBD-loaded exosomes platform. The Consumer Wellness segment develops and markets a wide portfolio of innovative self-care products.

Innocan Pharma appears to promote a collaborative and innovative culture, emphasizing scientific excellence and a commitment to advancing healthcare through the development of cannabinoid-based treatments. The company actively seeks out and engages with leading experts in the field, forming strong partnerships with research institutions and industry leaders. This suggests a culture that values knowledge sharing, open communication, and a willingness to take risks in pursuit of groundbreaking solutions.